Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
(-)-englerin A + Pralatrexate
|
DC9X7XN
|
(-)-englerin A
|
Ewing sarcoma (Cell Line: TC-71)
|
[3] |
|
10-hydroxycamptothecin + Pralatrexate
|
DC100RS
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
ABIRATERONE + Pralatrexate
|
DCUXLGJ
|
ABIRATERONE
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
ABIRATERONE + Pralatrexate
|
DCXRKKP
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
ABIRATERONE + Pralatrexate
|
DCEOZP5
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
ABIRATERONE + Pralatrexate
|
DCWEQH5
|
ABIRATERONE
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
ABT-263 + Pralatrexate
|
DCOCU9T
|
ABT-263
|
Ewing sarcoma (Cell Line: TC-71)
|
[4] |
|
Amonafide + Pralatrexate
|
DC6MHRH
|
Amonafide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Amonafide + Pralatrexate
|
DCILAXN
|
Amonafide
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Amonafide + Pralatrexate
|
DCQ09LU
|
Amonafide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Amonafide + Pralatrexate
|
DCHHYSC
|
Amonafide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Amonafide + Pralatrexate
|
DCRBCR9
|
Amonafide
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Amonafide + Pralatrexate
|
DCR4QEZ
|
Amonafide
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Amonafide + Pralatrexate
|
DCG9LXW
|
Amonafide
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Amonafide + Pralatrexate
|
DCZMKJY
|
Amonafide
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Amonafide + Pralatrexate
|
DC4GDJ3
|
Amonafide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Anastrozole + Pralatrexate
|
DC0023Y
|
Anastrozole
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Anastrozole + Pralatrexate
|
DCXVF96
|
Anastrozole
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Anastrozole + Pralatrexate
|
DCXQAWQ
|
Anastrozole
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Anastrozole + Pralatrexate
|
DCBP1B4
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Anastrozole + Pralatrexate
|
DCPRABA
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Anastrozole + Pralatrexate
|
DCJG4Z7
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Anastrozole + Pralatrexate
|
DCS4OW9
|
Anastrozole
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Anastrozole + Pralatrexate
|
DCUPT28
|
Anastrozole
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Arfolitixorin + Pralatrexate
|
DCTLVAJ
|
Arfolitixorin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Arfolitixorin + Pralatrexate
|
DCKKQHE
|
Arfolitixorin
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Artemether + Pralatrexate
|
DCSWTQ0
|
Artemether
|
Ewing sarcoma (Cell Line: TC-71)
|
[3] |
|
Azacitidine + Pralatrexate
|
DCWP73M
|
Azacitidine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Azacitidine + Pralatrexate
|
DCJ1F0R
|
Azacitidine
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Azacitidine + Pralatrexate
|
DCZYN8L
|
Azacitidine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Azacitidine + Pralatrexate
|
DCKXII4
|
Azacitidine
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Azacitidine + Pralatrexate
|
DCPHEJC
|
Azacitidine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Azacitidine + Pralatrexate
|
DCWJWBK
|
Azacitidine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Azacitidine + Pralatrexate
|
DC08S54
|
Azacitidine
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Azacitidine + Pralatrexate
|
DC1HMSF
|
Azacitidine
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
AZD7762 + Pralatrexate
|
DC8Q85E
|
AZD7762
|
Ewing sarcoma (Cell Line: TC-71)
|
[3] |
|
BIO-300 + Pralatrexate
|
DC9W0AH
|
BIO-300
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
BIO-300 + Pralatrexate
|
DCWJA87
|
BIO-300
|
Glioma (Cell Line: SF-268)
|
[3] |
|
BIO-300 + Pralatrexate
|
DC51QZQ
|
BIO-300
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
BIO-300 + Pralatrexate
|
DCEOULW
|
BIO-300
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
BIO-300 + Pralatrexate
|
DC4PTVZ
|
BIO-300
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
BIO-300 + Pralatrexate
|
DC3SYXH
|
BIO-300
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
BIO-300 + Pralatrexate
|
DC5JUYU
|
BIO-300
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
BIO-300 + Pralatrexate
|
DC2KZN3
|
BIO-300
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
BIO-300 + Pralatrexate
|
DCMF0HK
|
BIO-300
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
BIO-300 + Pralatrexate
|
DCUZSPM
|
BIO-300
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
BIO-300 + Pralatrexate
|
DC1R7KU
|
BIO-300
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
BIO-300 + Pralatrexate
|
DCY20O5
|
BIO-300
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
BIO-300 + Pralatrexate
|
DCIG22O
|
BIO-300
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Bleomycin + Pralatrexate
|
DCVL1A6
|
Bleomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Bleomycin + Pralatrexate
|
DCF4T63
|
Bleomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Bleomycin + Pralatrexate
|
DCIPZKS
|
Bleomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Bleomycin + Pralatrexate
|
DCWD1XL
|
Bleomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Bleomycin + Pralatrexate
|
DCPS5DI
|
Bleomycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Bleomycin + Pralatrexate
|
DC9VMU9
|
Bleomycin
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Bleomycin + Pralatrexate
|
DCRFQUV
|
Bleomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Bleomycin + Pralatrexate
|
DCMBGLI
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Bleomycin + Pralatrexate
|
DCFBLC0
|
Bleomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Bleomycin + Pralatrexate
|
DCTFCYE
|
Bleomycin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Cabazitaxel + Pralatrexate
|
DC2AR02
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DC1TA7I
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCEBD3A
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DC1ZUQH
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DC7HSAP
|
Cabazitaxel
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DC1KX21
|
Cabazitaxel
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCMB0K3
|
Cabazitaxel
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCPVYO7
|
Cabazitaxel
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCW1L3K
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DC0WX4Q
|
Cabazitaxel
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCOX79X
|
Cabazitaxel
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DC61SXM
|
Cabazitaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCNJXT8
|
Cabazitaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DC4EP2I
|
Cabazitaxel
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DC8WWHF
|
Cabazitaxel
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCR42AQ
|
Cabazitaxel
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCXXU90
|
Cabazitaxel
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCFZOG2
|
Cabazitaxel
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCZTP9V
|
Cabazitaxel
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCTOH5Z
|
Cabazitaxel
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCAHHXF
|
Cabazitaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DC5O6S6
|
Cabazitaxel
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Cabazitaxel + Pralatrexate
|
DCJDBPA
|
Cabazitaxel
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Cabazitaxel + Pralatrexate
|
DC9PHCA
|
Cabazitaxel
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Cabazitaxel + Pralatrexate
|
DCDEG3C
|
Cabazitaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Cabazitaxel + Pralatrexate
|
DCSWP76
|
Cabazitaxel
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Crizotinib + Pralatrexate
|
DC4772R
|
Crizotinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Crizotinib + Pralatrexate
|
DCBZ196
|
Crizotinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Crizotinib + Pralatrexate
|
DCMACSR
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Crizotinib + Pralatrexate
|
DCPWIWK
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Crizotinib + Pralatrexate
|
DCPLQIF
|
Crizotinib
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Crizotinib + Pralatrexate
|
DC48BWR
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Dacarbazine + Pralatrexate
|
DC9G3I1
|
Dacarbazine
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Dactinomycin + Pralatrexate
|
DCEY1UP
|
Dactinomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Dasatinib + Pralatrexate
|
DCIGJKO
|
Dasatinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Dasatinib + Pralatrexate
|
DCC1WWM
|
Dasatinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Dasatinib + Pralatrexate
|
DCPWIP9
|
Dasatinib
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Dasatinib + Pralatrexate
|
DC2SIW1
|
Dasatinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Dasatinib + Pralatrexate
|
DCX1OHC
|
Dasatinib
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Dexrazoxane + Pralatrexate
|
DCPFC9A
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
DFN-15 + Pralatrexate
|
DC21VBZ
|
DFN-15
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
DFN-15 + Pralatrexate
|
DC00OJ5
|
DFN-15
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
DFN-15 + Pralatrexate
|
DC0NSEC
|
DFN-15
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
DFN-15 + Pralatrexate
|
DCC531X
|
DFN-15
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
DFN-15 + Pralatrexate
|
DC89OKB
|
DFN-15
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Docetaxel + Pralatrexate
|
DCVMUJH
|
Docetaxel
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Docetaxel + Pralatrexate
|
DC5S2KG
|
Docetaxel
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Epirubicin + Pralatrexate
|
DCP6T5N
|
Epirubicin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Epirubicin + Pralatrexate
|
DCQ58D9
|
Epirubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Epirubicin + Pralatrexate
|
DC3GDFQ
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Epirubicin + Pralatrexate
|
DC54SDH
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Epirubicin + Pralatrexate
|
DCJNIMS
|
Epirubicin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Epirubicin + Pralatrexate
|
DCE5X13
|
Epirubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Epirubicin + Pralatrexate
|
DCA7CN4
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Epirubicin + Pralatrexate
|
DC6MFOD
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Estramustine + Pralatrexate
|
DCHIETW
|
Estramustine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Fludarabine + Pralatrexate
|
DCD1WQU
|
Fludarabine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Fludarabine + Pralatrexate
|
DCAST25
|
Fludarabine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
FORMESTANE + Pralatrexate
|
DCDIPL0
|
FORMESTANE
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
FORMESTANE + Pralatrexate
|
DCFRSRH
|
FORMESTANE
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
FORMESTANE + Pralatrexate
|
DCU1IYA
|
FORMESTANE
|
Glioma (Cell Line: SF-295)
|
[3] |
|
FORMESTANE + Pralatrexate
|
DCVGK60
|
FORMESTANE
|
Glioma (Cell Line: SF-268)
|
[3] |
|
FORMESTANE + Pralatrexate
|
DCXPSQ0
|
FORMESTANE
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
FORMESTANE + Pralatrexate
|
DC6SNWM
|
FORMESTANE
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Fulvestrant + Pralatrexate
|
DCFFYHB
|
Fulvestrant
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Gefitinib + Pralatrexate
|
DCDI5KT
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Gefitinib + Pralatrexate
|
DCATZVT
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Hepzato + Pralatrexate
|
DCFNRUF
|
Hepzato
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Hepzato + Pralatrexate
|
DCQ9U8X
|
Hepzato
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Hepzato + Pralatrexate
|
DCH92OX
|
Hepzato
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Idarubicin + Pralatrexate
|
DCVA6GE
|
Idarubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Idarubicin + Pralatrexate
|
DC9TWWT
|
Idarubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Imatinib + Pralatrexate
|
DCWGM0O
|
Imatinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Imatinib + Pralatrexate
|
DCC6UGL
|
Imatinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Imatinib + Pralatrexate
|
DC3ND2K
|
Imatinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Indazole derivative 5 + Pralatrexate
|
DCDX1HD
|
Indazole derivative 5
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Indazole derivative 5 + Pralatrexate
|
DC6NUZ6
|
Indazole derivative 5
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Indazole derivative 5 + Pralatrexate
|
DCFL9OB
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Indazole derivative 5 + Pralatrexate
|
DCEYO90
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Indazole derivative 5 + Pralatrexate
|
DCRLRPD
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Indazole derivative 5 + Pralatrexate
|
DC0CLGE
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Indazole derivative 5 + Pralatrexate
|
DCPTMXH
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Indazole derivative 5 + Pralatrexate
|
DC9TAXZ
|
Indazole derivative 5
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
JNK-IN-8 + Pralatrexate
|
DCHAQPE
|
JNK-IN-8
|
Glioma (Cell Line: SF-295)
|
[3] |
|
JNK-IN-8 + Pralatrexate
|
DCLU7PJ
|
JNK-IN-8
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
JNK-IN-8 + Pralatrexate
|
DCDOLZV
|
JNK-IN-8
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
JNK-IN-8 + Pralatrexate
|
DCRMT6E
|
JNK-IN-8
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
JNK-IN-8 + Pralatrexate
|
DCAD8CH
|
JNK-IN-8
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
JNK-IN-8 + Pralatrexate
|
DCQ3P75
|
JNK-IN-8
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Lapatinib + Pralatrexate
|
DC5EUV5
|
Lapatinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Lapatinib + Pralatrexate
|
DCICA2U
|
Lapatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Lapatinib + Pralatrexate
|
DCBA6TH
|
Lapatinib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Lapatinib + Pralatrexate
|
DCQROGI
|
Lapatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Lapatinib + Pralatrexate
|
DC5N8P0
|
Lapatinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Lenalidomide + Pralatrexate
|
DC8VRJJ
|
Lenalidomide
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Lenalidomide + Pralatrexate
|
DC6E0BT
|
Lenalidomide
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Lenalidomide + Pralatrexate
|
DCJFWN9
|
Lenalidomide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Lenalidomide + Pralatrexate
|
DCGTDCK
|
Lenalidomide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Letrozole + Pralatrexate
|
DC8QUXT
|
Letrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Letrozole + Pralatrexate
|
DC44ANT
|
Letrozole
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Letrozole + Pralatrexate
|
DCVJEX1
|
Letrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Mechlorethamine + Pralatrexate
|
DCI94RW
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Mechlorethamine + Pralatrexate
|
DCBU5CK
|
Mechlorethamine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Mitomycin + Pralatrexate
|
DCQ6FZJ
|
Mitomycin
|
Ewing sarcoma (Cell Line: TC-71)
|
[3] |
|
MK-1775 + Pralatrexate
|
DCA6MCY
|
MK-1775
|
Ewing sarcoma (Cell Line: TC-71)
|
[3] |
|
MK-1775 + Pralatrexate
|
DC1OE1P
|
MK-1775
|
Hodgkin lymphoma (Cell Line: U-HO1)
|
[3] |
|
Nilotinib + Pralatrexate
|
DC9DGAV
|
Nilotinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Nilotinib + Pralatrexate
|
DCDSIBN
|
Nilotinib
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Nilotinib + Pralatrexate
|
DCZQQP2
|
Nilotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Nilotinib + Pralatrexate
|
DC0G2RW
|
Nilotinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Nilotinib + Pralatrexate
|
DCUEUUC
|
Nilotinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Nilotinib + Pralatrexate
|
DCNB118
|
Nilotinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Nilotinib + Pralatrexate
|
DCUIUYZ
|
Nilotinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
PD-0325901 + Pralatrexate
|
DCU94VI
|
PD-0325901
|
Hodgkin lymphoma (Cell Line: U-HO1)
|
[4] |
|
Pelitinib + Pralatrexate
|
DCR2NYO
|
Pelitinib
|
Ewing sarcoma (Cell Line: TC-71)
|
[3] |
|
Picoplatin + Pralatrexate
|
DC7LUCW
|
Picoplatin
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Picoplatin + Pralatrexate
|
DC8F6TI
|
Picoplatin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Picoplatin + Pralatrexate
|
DC2DJEG
|
Picoplatin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Picoplatin + Pralatrexate
|
DCL9YUA
|
Picoplatin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Picoplatin + Pralatrexate
|
DC693S8
|
Picoplatin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Picoplatin + Pralatrexate
|
DCYB8EO
|
Picoplatin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Picoplatin + Pralatrexate
|
DC4KVYE
|
Picoplatin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Plicamycin + Pralatrexate
|
DCUK2X3
|
Plicamycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Plicamycin + Pralatrexate
|
DC033E3
|
Plicamycin
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Plicamycin + Pralatrexate
|
DCQD70K
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Plicamycin + Pralatrexate
|
DC0AKF2
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Plicamycin + Pralatrexate
|
DCMEZ0Y
|
Plicamycin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Plicamycin + Pralatrexate
|
DCRK1WT
|
Plicamycin
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Plicamycin + Pralatrexate
|
DCTJ5C9
|
Plicamycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Plicamycin + Pralatrexate
|
DCEBT01
|
Plicamycin
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Plicamycin + Pralatrexate
|
DCEYG1D
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Plicamycin + Pralatrexate
|
DCQO5SY
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Plicamycin + Pralatrexate
|
DCM42IN
|
Plicamycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Plicamycin + Pralatrexate
|
DCUGH5K
|
Plicamycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Plicamycin + Pralatrexate
|
DC2K0G8
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Plicamycin + Pralatrexate
|
DCIHV63
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Plicamycin + Pralatrexate
|
DC42RNM
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Plicamycin + Pralatrexate
|
DCLZK63
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Plicamycin + Pralatrexate
|
DC7Y3R0
|
Plicamycin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Plicamycin + Pralatrexate
|
DCMZ2ZO
|
Plicamycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Plicamycin + Pralatrexate
|
DCOX30U
|
Plicamycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Plicamycin + Pralatrexate
|
DC2N53J
|
Plicamycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCDQRMG
|
PMID28460551-Compound-2
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCMAU46
|
PMID28460551-Compound-2
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCGN201
|
PMID28460551-Compound-2
|
Glioma (Cell Line: SF-539)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCTZC7I
|
PMID28460551-Compound-2
|
Glioma (Cell Line: SF-268)
|
[3] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCQUJ5X
|
PMID28460551-Compound-2
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DC58606
|
PMID28460551-Compound-2
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DC64O3I
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCZO0UT
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DC7RX4C
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DC10HXM
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DC2TLGN
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCCM0YI
|
PMID28460551-Compound-2
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCVZO79
|
PMID28460551-Compound-2
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCHWI4U
|
PMID28460551-Compound-2
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCFCN7D
|
PMID28460551-Compound-2
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
PMID28460551-Compound-2 + Pralatrexate
|
DCZZ6Q6
|
PMID28460551-Compound-2
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Pralatrexate + Pentostatin
|
DCFHLZT
|
Pentostatin
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Pralatrexate + Pentostatin
|
DCNCH59
|
Pentostatin
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Pralatrexate + Ixabepilone
|
DC7M4UU
|
Ixabepilone
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Pralatrexate + Ixabepilone
|
DCGGPPW
|
Ixabepilone
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Pralatrexate + Ixabepilone
|
DC45MNH
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Pralatrexate + Ixabepilone
|
DC31ALK
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Pralatrexate + Dactinomycin
|
DC1DU5B
|
Dactinomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Pralatrexate + Dactinomycin
|
DC3JVJF
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Pralatrexate + Dactinomycin
|
DCPBXHU
|
Dactinomycin
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Pralatrexate + Dactinomycin
|
DCFQJAN
|
Dactinomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Pralatrexate + Dactinomycin
|
DC3Y04E
|
Dactinomycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Pralatrexate + Cyclophosphamide
|
DC1ASQS
|
Cyclophosphamide
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Pralatrexate + Methotrexate
|
DC65E5O
|
Methotrexate
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Pralatrexate + Methotrexate
|
DCFS4T7
|
Methotrexate
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Pralatrexate + Methotrexate
|
DCB5C0A
|
Methotrexate
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Pralatrexate + Methotrexate
|
DC7B2QD
|
Methotrexate
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Pralatrexate + Methotrexate
|
DCB7YFH
|
Methotrexate
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Pralatrexate + Methotrexate
|
DC5NUXL
|
Methotrexate
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Pralatrexate + Methotrexate
|
DC41Z51
|
Methotrexate
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Pralatrexate + Methotrexate
|
DCG5UU4
|
Methotrexate
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Pralatrexate + Isoniazid
|
DCK1XAF
|
Isoniazid
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Pralatrexate + Isoniazid
|
DCLXPXN
|
Isoniazid
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DCRAXZ1
|
Arsenic trioxide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DCZCG7S
|
Arsenic trioxide
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DCFCS04
|
Arsenic trioxide
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DCYMR2B
|
Arsenic trioxide
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DCBFCT5
|
Arsenic trioxide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DC7ECE7
|
Arsenic trioxide
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Pralatrexate + Topetecan
|
DCAJ35F
|
Topetecan
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Pralatrexate + Topetecan
|
DCQO62J
|
Topetecan
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Pralatrexate + Mitomycin
|
DCXM645
|
Mitomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Pralatrexate + Mitomycin
|
DCNIQGG
|
Mitomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Pralatrexate + Altretamine
|
DCIYRQ2
|
Altretamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Pralatrexate + Bortezomib
|
DCXFSXM
|
Bortezomib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Pralatrexate + Bortezomib
|
DCZRZKJ
|
Bortezomib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Pralatrexate + Bortezomib
|
DC0GICH
|
Bortezomib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Pralatrexate + Bortezomib
|
DCMS7VU
|
Bortezomib
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Pralatrexate + Cisplatin
|
DC2DW1L
|
Cisplatin
|
Glioma (Cell Line: SF-268)
|
[3] |
|
Pralatrexate + Chlorambucil
|
DCKTHMC
|
Chlorambucil
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Pralatrexate + Pomalidomide
|
DC9Q5PO
|
Pomalidomide
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Pralatrexate + Mepacrine
|
DC7XVTV
|
Mepacrine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
Pralatrexate + Mepacrine
|
DCQBVC5
|
Mepacrine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCP76D8
|
PMID28870136-Compound-43
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCBSC5P
|
PMID28870136-Compound-43
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCOMCY1
|
PMID28870136-Compound-43
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Pralatrexate + Aminolevulinic Acid Hydrochloride
|
DCMP0SE
|
Aminolevulinic Acid Hydrochloride
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Pralatrexate + Busulfan
|
DCI4N53
|
Busulfan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Pralatrexate + Ibrutinib
|
DCKHWMU
|
Ibrutinib
|
Diffuse large B cell lymphoma (Cell Line: TMD8)
|
[3] |
|
Pralatrexate + Pentostatin
|
DCO8QA8
|
Pentostatin
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Pralatrexate + Ixabepilone
|
DCAK4HZ
|
Ixabepilone
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Pralatrexate + Ixabepilone
|
DC83LZ8
|
Ixabepilone
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
Pralatrexate + Ixabepilone
|
DC1Z9I7
|
Ixabepilone
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Pralatrexate + Ixabepilone
|
DC1X7FW
|
Ixabepilone
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Pralatrexate + Ixabepilone
|
DCNFCJQ
|
Ixabepilone
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Pralatrexate + Ixabepilone
|
DCH8WVU
|
Ixabepilone
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Pralatrexate + Cyclophosphamide
|
DC4ZIJN
|
Cyclophosphamide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Pralatrexate + Methotrexate
|
DCADBK1
|
Methotrexate
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Pralatrexate + Methotrexate
|
DCEN5CG
|
Methotrexate
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Pralatrexate + Methotrexate
|
DCGJH0Q
|
Methotrexate
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Pralatrexate + Topetecan
|
DCSNVM4
|
Topetecan
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Pralatrexate + Altretamine
|
DCENKQX
|
Altretamine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Pralatrexate + Bortezomib
|
DCTS7N2
|
Bortezomib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Pralatrexate + Chlorambucil
|
DCC3W9C
|
Chlorambucil
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Pralatrexate + Pomalidomide
|
DCGDKOE
|
Pomalidomide
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCOI9G6
|
PMID28870136-Compound-43
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Pralatrexate + Pentostatin
|
DC2ILR1
|
Pentostatin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Pralatrexate + Pentostatin
|
DCI5TA6
|
Pentostatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Pralatrexate + Pentostatin
|
DCLUHPB
|
Pentostatin
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Pralatrexate + Pentostatin
|
DC39TRE
|
Pentostatin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DCG52FM
|
Ixabepilone
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DC76LTM
|
Ixabepilone
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DC94TVP
|
Ixabepilone
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DCMMZCL
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DC3XOXY
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DC8T9SJ
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DCPX9M9
|
Ixabepilone
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DC6CWSM
|
Ixabepilone
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DCAT01W
|
Ixabepilone
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DCHO683
|
Ixabepilone
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DCY5CN8
|
Ixabepilone
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DCZWMBC
|
Ixabepilone
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DC5MIYT
|
Ixabepilone
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DC1IODN
|
Ixabepilone
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DCVDIQ1
|
Ixabepilone
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DCL995A
|
Ixabepilone
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DCZIF49
|
Ixabepilone
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Pralatrexate + Ixabepilone
|
DC41ZAT
|
Ixabepilone
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Pralatrexate + Methotrexate
|
DCWUV3W
|
Methotrexate
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Pralatrexate + Methotrexate
|
DCR4JAO
|
Methotrexate
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Pralatrexate + Methotrexate
|
DC4HNDA
|
Methotrexate
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Pralatrexate + Methotrexate
|
DCYZ8CW
|
Methotrexate
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Pralatrexate + Methotrexate
|
DCLDYQF
|
Methotrexate
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Pralatrexate + Methotrexate
|
DC0FYMM
|
Methotrexate
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Pralatrexate + Methotrexate
|
DC2O41S
|
Methotrexate
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Pralatrexate + Methotrexate
|
DCZSJBS
|
Methotrexate
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Pralatrexate + Methotrexate
|
DC4TQ3O
|
Methotrexate
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Pralatrexate + Methotrexate
|
DCFM3T7
|
Methotrexate
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Pralatrexate + Isoniazid
|
DCCUEAX
|
Isoniazid
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DC6XVWF
|
Arsenic trioxide
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DC8OS0G
|
Arsenic trioxide
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DC0K0H0
|
Arsenic trioxide
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DCPL1BR
|
Arsenic trioxide
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DCR9908
|
Arsenic trioxide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DCF7QPZ
|
Arsenic trioxide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Pralatrexate + Topetecan
|
DC2TVTJ
|
Topetecan
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Pralatrexate + Topetecan
|
DCBTYYB
|
Topetecan
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Pralatrexate + Topetecan
|
DCH78PJ
|
Topetecan
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Pralatrexate + Topetecan
|
DC367PT
|
Topetecan
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Pralatrexate + Topetecan
|
DCAATG2
|
Topetecan
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Pralatrexate + Topetecan
|
DC1FIWA
|
Topetecan
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Pralatrexate + Topetecan
|
DCEE55F
|
Topetecan
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Pralatrexate + Topetecan
|
DC22M4D
|
Topetecan
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Pralatrexate + Topetecan
|
DCTGGFL
|
Topetecan
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Pralatrexate + Topetecan
|
DC7JHHT
|
Topetecan
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Pralatrexate + Ifosfamide
|
DC65S39
|
Ifosfamide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Pralatrexate + Ifosfamide
|
DCJLJZC
|
Ifosfamide
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Pralatrexate + Ifosfamide
|
DCOHDUE
|
Ifosfamide
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Pralatrexate + Bendamustine hydrochloride
|
DCEEQZ1
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Pralatrexate + Bendamustine hydrochloride
|
DC4YKOX
|
Bendamustine hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Pralatrexate + Mitomycin
|
DCHIAGU
|
Mitomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Pralatrexate + Mitomycin
|
DC01YYT
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Pralatrexate + Mitomycin
|
DCM3DFA
|
Mitomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Pralatrexate + Altretamine
|
DCTSTP9
|
Altretamine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Pralatrexate + Bortezomib
|
DCF2BZH
|
Bortezomib
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Pralatrexate + Bortezomib
|
DCZCSQQ
|
Bortezomib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Pralatrexate + Bortezomib
|
DCWZDVL
|
Bortezomib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Pralatrexate + Bortezomib
|
DCXC87O
|
Bortezomib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Pralatrexate + Cisplatin
|
DCTBTZ5
|
Cisplatin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Pralatrexate + Chlorambucil
|
DC7KWU2
|
Chlorambucil
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Pralatrexate + Chlorambucil
|
DCV0NZT
|
Chlorambucil
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Pralatrexate + Chlorambucil
|
DCU4PGP
|
Chlorambucil
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Pralatrexate + Chlorambucil
|
DCEW6E0
|
Chlorambucil
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Pralatrexate + ER819762
|
DCTF9VG
|
ER819762
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Pralatrexate + Pomalidomide
|
DCWCTPE
|
Pomalidomide
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Pralatrexate + Mepacrine
|
DCDY0IP
|
Mepacrine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Pralatrexate + Mepacrine
|
DCOQJVY
|
Mepacrine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCQ8HWM
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCMVYWD
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCTU4WV
|
PMID28870136-Compound-43
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCARY3Q
|
PMID28870136-Compound-43
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCQH23Y
|
PMID28870136-Compound-43
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Pralatrexate + Aminolevulinic Acid Hydrochloride
|
DCBSQXS
|
Aminolevulinic Acid Hydrochloride
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Pralatrexate + Busulfan
|
DC1D1SU
|
Busulfan
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Pralatrexate + Busulfan
|
DCZKWGA
|
Busulfan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Pralatrexate
|
DCX5DCW
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Raloxifene + Pralatrexate
|
DCRV0C0
|
Raloxifene
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Raloxifene + Pralatrexate
|
DCZ555U
|
Raloxifene
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Raloxifene + Pralatrexate
|
DCPLY02
|
Raloxifene
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Raloxifene + Pralatrexate
|
DCSN6OH
|
Raloxifene
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Raloxifene + Pralatrexate
|
DCBU4N1
|
Raloxifene
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Raloxifene + Pralatrexate
|
DCG2S95
|
Raloxifene
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Pralatrexate
|
DCFD0IA
|
Raloxifene
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Raloxifene + Pralatrexate
|
DCPSBI7
|
Raloxifene
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Pralatrexate
|
DC0VXLQ
|
Raloxifene
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Pralatrexate
|
DCI0ZVY
|
Raloxifene
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Romidepsin + Pralatrexate
|
DCH2142
|
Romidepsin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Romidepsin + Pralatrexate
|
DCUCPBC
|
Romidepsin
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Ruxolitinib + Pralatrexate
|
DCNUJLZ
|
Ruxolitinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Ruxolitinib + Pralatrexate
|
DCZ0G8B
|
Ruxolitinib
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Ruxolitinib + Pralatrexate
|
DCKUBMC
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Ruxolitinib + Pralatrexate
|
DCG85PZ
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Ruxolitinib + Pralatrexate
|
DC7M79T
|
Ruxolitinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
SCH 727965 + Pralatrexate
|
DC92THY
|
SCH 727965
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
SCH 727965 + Pralatrexate
|
DCV86GJ
|
SCH 727965
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
SCH 727965 + Pralatrexate
|
DCE9E4W
|
SCH 727965
|
Glioma (Cell Line: SF-295)
|
[3] |
|
SCH 727965 + Pralatrexate
|
DC1IQAG
|
SCH 727965
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
SCH 727965 + Pralatrexate
|
DCNTZD1
|
SCH 727965
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
SCH 727965 + Pralatrexate
|
DCM2BSB
|
SCH 727965
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
SCH 727965 + Pralatrexate
|
DCX8F1X
|
SCH 727965
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Sirolimus + Pralatrexate
|
DC0ZTXE
|
Sirolimus
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Sirolimus + Pralatrexate
|
DCB1DNK
|
Sirolimus
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Sirolimus + Pralatrexate
|
DCM7YNL
|
Sirolimus
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Sirolimus + Pralatrexate
|
DC48KUV
|
Sirolimus
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Sirolimus + Pralatrexate
|
DCN5NUN
|
Sirolimus
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Sorafenib + Pralatrexate
|
DCVSUQX
|
Sorafenib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Sorafenib + Pralatrexate
|
DCJWQ3V
|
Sorafenib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Sorafenib + Pralatrexate
|
DCIMXCX
|
Sorafenib
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Sorafenib + Pralatrexate
|
DC3MMDC
|
Sorafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Sorafenib + Pralatrexate
|
DCU2BBC
|
Sorafenib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Sorafenib + Pralatrexate
|
DCIOR5Z
|
Sorafenib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
SY-1425 + Pralatrexate
|
DC8I02X
|
SY-1425
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
SY-1425 + Pralatrexate
|
DCK07QP
|
SY-1425
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
SY-1425 + Pralatrexate
|
DCG4YN6
|
SY-1425
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Taxol + Pralatrexate
|
DCUGUQO
|
Taxol
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Taxol + Pralatrexate
|
DCX7J5N
|
Taxol
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Taxol + Pralatrexate
|
DCYRLRO
|
Taxol
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Taxol + Pralatrexate
|
DC8PA5U
|
Taxol
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
TEM + Pralatrexate
|
DCTRJZ2
|
TEM
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[3] |
|
TEM + Pralatrexate
|
DCFRD18
|
TEM
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
TEM + Pralatrexate
|
DCSZL99
|
TEM
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
TEM + Pralatrexate
|
DCMEHY4
|
TEM
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
TEM + Pralatrexate
|
DCGWX9B
|
TEM
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
TEM + Pralatrexate
|
DCZW6SD
|
TEM
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
TEM + Pralatrexate
|
DCXQ07T
|
TEM
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
TEM + Pralatrexate
|
DCN7M1F
|
TEM
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
TEM + Pralatrexate
|
DCWZKMY
|
TEM
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
TEM + Pralatrexate
|
DCKB49D
|
TEM
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Thioguanine + Pralatrexate
|
DCXG8QG
|
Thioguanine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Thioguanine + Pralatrexate
|
DCGRHUF
|
Thioguanine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[3] |
|
Thioguanine + Pralatrexate
|
DCQAH30
|
Thioguanine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Thioguanine + Pralatrexate
|
DC04OM5
|
Thioguanine
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Thioguanine + Pralatrexate
|
DCNCG5S
|
Thioguanine
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Thioguanine + Pralatrexate
|
DCNY84B
|
Thioguanine
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Thioguanine + Pralatrexate
|
DCUMTE4
|
Thioguanine
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Thioguanine + Pralatrexate
|
DCNPZDN
|
Thioguanine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Topotecan + Pralatrexate
|
DCKLZH0
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Topotecan + Pralatrexate
|
DCWMOF2
|
Topotecan
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Topotecan + Pralatrexate
|
DC1Y31T
|
Topotecan
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Topotecan + Pralatrexate
|
DCFLFBQ
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Topotecan + Pralatrexate
|
DCXDWYI
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Topotecan + Pralatrexate
|
DC2BKCK
|
Topotecan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Topotecan + Pralatrexate
|
DCN8X2Z
|
Topotecan
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Topotecan + Pralatrexate
|
DCU4XMG
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Topotecan + Pralatrexate
|
DCZ0RPR
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Topotecan + Pralatrexate
|
DCEKO2O
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Topotecan + Pralatrexate
|
DCF6CEH
|
Topotecan
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Topotecan + Pralatrexate
|
DC91QQO
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Triapine + Pralatrexate
|
DCGB3QB
|
Triapine
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Triapine + Pralatrexate
|
DC9LHB9
|
Triapine
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Triapine + Pralatrexate
|
DCDQ46O
|
Triapine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Triapine + Pralatrexate
|
DC2IEP5
|
Triapine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Triapine + Pralatrexate
|
DCQWRIK
|
Triapine
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Triapine + Pralatrexate
|
DCIPBR6
|
Triapine
|
Glioma (Cell Line: SF-539)
|
[4] |
|
Triapine + Pralatrexate
|
DCS0QFV
|
Triapine
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Trifluridine + Pralatrexate
|
DCY946Z
|
Trifluridine
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Trifluridine + Pralatrexate
|
DCZ0K1O
|
Trifluridine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Trifluridine + Pralatrexate
|
DCLCJVI
|
Trifluridine
|
Glioma (Cell Line: SF-295)
|
[3] |
|
Trifluridine + Pralatrexate
|
DCNVBID
|
Trifluridine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[3] |
|
Trifluridine + Pralatrexate
|
DC1CX9H
|
Trifluridine
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Trifluridine + Pralatrexate
|
DC45BCD
|
Trifluridine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Trifluridine + Pralatrexate
|
DCS7MZU
|
Trifluridine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Trifluridine + Pralatrexate
|
DCPEG4L
|
Trifluridine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Trifluridine + Pralatrexate
|
DCB01JO
|
Trifluridine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Trifluridine + Pralatrexate
|
DCMUZ35
|
Trifluridine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Trifluridine + Pralatrexate
|
DCHPKY9
|
Trifluridine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Trifluridine + Pralatrexate
|
DCCRGN6
|
Trifluridine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Uracil mustard + Pralatrexate
|
DCIVJE4
|
Uracil mustard
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[3] |
|
Uracil mustard + Pralatrexate
|
DCQ4LCN
|
Uracil mustard
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Uracil mustard + Pralatrexate
|
DCXYF3U
|
Uracil mustard
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Uracil mustard + Pralatrexate
|
DCUS4D5
|
Uracil mustard
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Uracil mustard + Pralatrexate
|
DCZGJNX
|
Uracil mustard
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Uracil mustard + Pralatrexate
|
DCYZ219
|
Uracil mustard
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Uracil mustard + Pralatrexate
|
DC9H470
|
Uracil mustard
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Valrubicin + Pralatrexate
|
DC352PG
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Valrubicin + Pralatrexate
|
DCS6ETS
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Valrubicin + Pralatrexate
|
DC4FMOM
|
Valrubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Valrubicin + Pralatrexate
|
DCH1DQI
|
Valrubicin
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Valrubicin + Pralatrexate
|
DC0ZOCC
|
Valrubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Valrubicin + Pralatrexate
|
DC3GAL2
|
Valrubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Valrubicin + Pralatrexate
|
DCD2U6I
|
Valrubicin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Valrubicin + Pralatrexate
|
DCNJJ65
|
Valrubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Valrubicin + Pralatrexate
|
DCOHMQX
|
Valrubicin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Valrubicin + Pralatrexate
|
DC2MPRA
|
Valrubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Vandetanib + Pralatrexate
|
DC1SNWR
|
Vandetanib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Vandetanib + Pralatrexate
|
DC08761
|
Vandetanib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DC2OBHX
|
Vemurafenib
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Vemurafenib + Pralatrexate
|
DCF6MI1
|
Vemurafenib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Vemurafenib + Pralatrexate
|
DCTWYIE
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Vemurafenib + Pralatrexate
|
DC91KK3
|
Vemurafenib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DCSOI0K
|
Vemurafenib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DCQN6LK
|
Vemurafenib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DC1RVM0
|
Vemurafenib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DC8QUQ9
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DCXN20E
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DC5H598
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DCMTEEO
|
Vemurafenib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Vemurafenib + Pralatrexate
|
DC2DVFT
|
Vemurafenib
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Vinflunine + Pralatrexate
|
DCS4196
|
Vinflunine
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Vinflunine + Pralatrexate
|
DCUS54N
|
Vinflunine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Vinflunine + Pralatrexate
|
DCD3UCV
|
Vinflunine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Vismodegib + Pralatrexate
|
DCQWDAG
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Vismodegib + Pralatrexate
|
DC92X9O
|
Vismodegib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Vismodegib + Pralatrexate
|
DCXALEE
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Vismodegib + Pralatrexate
|
DCNVQ9H
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
